A Glimpse into the Future of Analytical Instrument Design?
-
By
-
Helen Bristow
-
James Strachan
-
October 7, 2026
-
7 min
By
Helen Bristow
James Strachan
October 7, 2026
by Helen Bristow, James Strachan
October 7, 2026
In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.
September 21, 2026
The Precision Pathology Insights webinar series provides expert guidance and essential approaches to help enhance your confidence in Combined Positive Score (CPS) evaluation and strengthen your PD-L1 proficiency.
October 6, 2026